Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IO-202 · 1 trial · 1 indication
safety and tolerability as measured by the incidence of treatment-emergent adverse events.
DLTs as measured by the incidence during Cycle 1.
The number of study discontinuations due to AEs
| Arm | Type | Description |
|---|---|---|
| IO-202 Monotherapy (dose escalation) | EXPERIMENTAL | - |
| IO-202 dose escalation + pembrolizumab | EXPERIMENTAL | Increasing dose levels of IO-202 with fixed dose of pembrolizumab |
| IO-202 + pembrolizumab combination therapy (dose expansion) | EXPERIMENTAL | RP2D + pembrolizumab combination therapy in solid tumor cohorts |
| Name | Type | Description |
|---|---|---|
| IO-202 | BIOLOGICAL | IO-202 given as monotherapy |
| IO-202 + pembrolizumab combination therapy | BIOLOGICAL | IO-202 and fixed dose pembrolizumab combination therapy |
| RP2D of IO-202 + pembrolizumab combination therapy in multiple solid tumor types | BIOLOGICAL | Expansion cohorts of the RP2D of IO-202 and fixed dose pembrolizumab combination therapy in multiple tumor types. |
Inclusion Criteria: 1. Subject must be ≥18 years old. 2. Part 1 - Dose Escalation: Subject must have any histologically or cytologically confirmed advanced or metastatic solid tumor and has received, has been intolerant to, or has been ineligible for standard systemic therapy known to confer clinic...
IO-202 is an investigational monoclonal antibody being studied for the treatment of solid tumors in adults. It is currently in Phase 1 clinical development, with a completed dose-escalation and dose-expansion study evaluating IO-202 alone and in combination with pembrolizumab in patients with solid tumors.
IO-202 is a monoclonal antibody designed to target a specific molecular pathway involved in solid tumor growth. The exact molecular target has not been disclosed in available clinical trial information, but the drug is being investigated for its potential to treat adult solid tumors.
IO-202 is being developed by cbdMD, Inc., a company traded on the NYSE American under the ticker symbol YCBD. The company is conducting clinical research to evaluate the safety and efficacy of IO-202 in patients with solid tumors.
IO-202 is in Phase 1 clinical development. A Phase 1 dose-escalation and dose-expansion study has been completed, with 22 patients enrolled. The drug is investigational and has not been approved by regulatory authorities for any indication.
IO-202 has been studied in one clinical trial, registered as NCT05309187. This was a Phase 1 dose-escalation and dose-expansion study of IO-202 alone and in combination with pembrolizumab in adult patients with solid tumors. The trial was completed in the United States.
No, IO-202 is not the same as pembrolizumab. IO-202 is an investigational monoclonal antibody being developed by cbdMD, Inc., while pembrolizumab is an approved immunotherapy drug. In the clinical trial NCT05309187, IO-202 was studied both alone and in combination with pembrolizumab.